Theravance Biopharma, Inc.
TBPHHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeTheravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. Valued at $886.8M, TBPH is a small-cap name in its sector. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
Market Cap
$886.8M
Beta
0.24
P/E (TTM)
16.42
P/E (Fwd)
13.40
EPS (TTM)
$1.04
EPS (Fwd)
$1.27
ROE
20.9%
ROA
1.3%
Cash
$387.7M
Total Debt
$38.6M
Free CF
$5.3M
52W Change
22.7%
Annual Financials
Cash vs Debt
Where TBPH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TBPH finished 1.79% above its 150-day moving average ($16.77) and 1.27% below its 200-day moving average ($17.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TBPH overbought or oversold?
At the September 3, 2026 close, TBPH's RSI(14) was 70.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $387.7M in cash comfortably exceeding the $38.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $5.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 20.9% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $51.3M (2022) to $107.5M (2025), reflecting a 109% increase over the period.
TBPH's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, TBPH has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Theravance Biopharma, Inc. and its sector.